Developers Base New Injury Stop Safety Syringe on Advanced Medical Grade of Hostaform® POM from Celanese

Cost-Effective Solution to Reduce Risk of Infection for Healthcare Workers

Sulzbach, Germany, Florence, Ky., Shanghai, PR China, Oct. 16, 2013 – Celanese Corporation (NYSE: CE), the global technology and specialty materials company, is showcasing at K 2013 in Düsseldorf, Germany, a new cost-effective medical application — the Injury Stop syringe that is based on Hostaform® acetal copolymer (POM), one of the medical technology polymers in the MT® portfolio.

High-performance Hostaform MT8U01 for medical applications enabled IBT systémes médicaux généraux and Société Plastique De Savoie, both of Hte. Savoie, France, to develop a novel safety mechanism for the new safety syringe that is designed to reduce the risk of becoming infected with hepatitis B, hepatitis C and HIV following accidental needle-stick injuries. After an injection, the healthcare worker rotates a piston 90 degrees, which retracts the piston and part of the syringe, including the needle, into the barrel of the syringe where it is locked for safe disposal. This simple procedure can help prevent accidental contact with the needle tip, especially for healthcare workers in developing countries.

“A single needle-stick injury can seriously endanger life. Healthcare workers helping others are especially at risk, and, where help is required the most, conventional safety syringes are too expensive to use,” said Wendy Johnson, medical marketing manager, engineered materials.

Hostaform MT8U01 combines good processability with dimensional stability and excellent sliding properties, which enabled the development team to reduce the cost of this innovative product. At only 10 cents per Injury Stop syringe, it is more than 50 percent less
expensive than conventional safety syringes. The additional cost per Injury Stop safety syringe vs. standard syringes, without protection against needle-stick injuries, is only 2 cents.

This cost saving can help medical facilities in developing countries, such as Africa and South America, effectively protect their healthcare workers from infections from accidental needle-stick injuries. This represents a significant step in the global fight against HIV, which occurs 10 times more often in 15 to 49 year-olds in Africa than in Europe, according to the World Health Organization (WHO).

Needle-stick injuries frequently result in serious consequences for health care workers. In 2002, the WHO reported that of the 35 million employees in healthcare worldwide, two million per year suffered a percutaneous exposure to infectious diseases. Just under 38 percent of the hepatitis B, 39 percent of the hepatitis C, and more than 4 percent of the HIV cases among healthcare professionals were due to needle-stick injuries according to the WHO.

“The engineered materials team at Celanese is pleased the developers at IBT systémes médicaux généraux and Société Plastique De Savoie succeeded in this safety syringe, based on Hostaform POM, that makes this important safety technology affordable and available worldwide,” said Johnson.

About Celanese

Celanese Corporation is a global technology leader in the production of differentiated chemistry solutions and specialty materials used in most major industries and consumer applications. With sales almost equally divided between North America, Europe and Asia, the company uses the full breadth of its global chemistry, technology and business expertise to create value for customers and the corporation. Celanese partners with customers to solve their most critical needs while making a positive impact on its communities and the world. Based in Dallas, Texas, Celanese employs approximately 7,600 employees worldwide and had 2012 net sales of $6.4 billion. For more information about Celanese Corporation and its product offerings, visit www.celanese.com or our blog at www.celaneseblog.com.

About IBT systémes médicaux généraux
IBT Smg SARL is a company established in 2006 and located at 14 bis Rue du Commerce in Annemasse (Hte. Savoie, France). IBT smg is a company with the legal form Ltd. Filing of the record was done with the RCS Thonon Les Bains in Haute Savoie. The company develops and sells medical and para-pharmaceuticals. The creators of IBT smg have great experience in the areas of society and participated in the past with success in developing new pharmaceuticals that have leveraged more than 20 patents around the world. One of the objectives of the company is to provide consultancy services for technological support to companies in the industrial sector through the creation of product, industrial monitoring and the establishment of production technologies.

About Société Plastique De Savoie

Molding company established in Reignier (Hte Savoie, France) have contracted with IBT smg the exclusive rights of manufacturing the Injury Stop syringe in exchange for manufacturing, process development and industrialization.

All registered trademarks are owned by Celanese or its affiliates.

Celanese Business Unit Contacts:

Engineered Materials: Americas:
Stephen Cushard, Global Marketing Communications Manager
+1-859-372-3164
Stephen.Cushard@celanese.com

Europe:
Henning Küll, Public Relations Manager
+49-69-45009-1797
Henning.Kuell@celanese.de

Asia:
Amber Zhao, Marketing Communications
+86-21-3861-9222
Tong.Zhao@celanese.com

Forward-Looking Statements
This release may contain “forward-looking statements,” which include information concerning the company’s plans, objectives, goals, strategies, future revenues or performance, capital expenditures, financing needs and other information that is not historical information. When used in this release, the words “outlook,” “forecast,” “estimates,” “expects,” “anticipates,” “projects,” “plans,” “intends,” “believes,” and variations of such words or similar expressions are intended to identify forward-looking statements. All forward-looking statements are based upon current expectations and beliefs and various assumptions. There can be no assurance that the company will realize these expectations or that these beliefs will prove correct. There are a number of risks and uncertainties that could cause actual results to differ materially from the forward-looking statements contained in this release. Numerous factors, many of which are beyond the company’s control, could cause actual results to differ materially from those expressed as forward-looking statements. These factors include the inability to obtain regulatory approvals of the transaction and satisfy conditions on the proposed terms and schedule and the possibility that the transaction does not close. Other risk factors include those that are discussed in the company’s filings with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it is made, and the company undertakes no obligation to update
any forward-looking statements to reflect events or circumstances after the date on which it is made or to reflect the occurrence of anticipated or unanticipated events or circumstances.

# # #